UBS Group
BCRX icon

UBS Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

UBS Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-4,200
Closed -$43K – 7637
2015
Q4 		$43K Hold
4,200
– – ﹤0.01% 5945
2015
Q3 		$48K Hold
4,200
– – ﹤0.01% 5874
2015
Q2 		$63K Hold
4,200
– – ﹤0.01% 5798
2015
Q1 		$38K Sell
4,200
-700
-14% -$7.25K ﹤0.01% 6300
2014
Q4 		$60K Buy
+4,900
New +$54.1K ﹤0.01% 6260

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

UBS Group's BCRX Position: Q1 2026 in Review

UBS Group reduced its BioCryst Pharmaceuticals (BCRX) stake by 6.1% in Q1 2026, selling an estimated $2.48M and leaving 4,943,994 shares worth $47.1M. The position accounts for 0.01% of the portfolio, ranked #1706.

UBS Group first reported a position in BCRX in Q4 2014 and has held it in 46 quarters since. The position peaked at $50.3M in Q2 2025. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • UBS Group held 4,943,994 shares of BioCryst Pharmaceuticals worth $47.1M as of Q1 2026.
  • UBS Group sold 319,920 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $2.48M.
  • BioCryst Pharmaceuticals made up 0.01% of UBS Group's portfolio in Q1 2026, its #1706 holding.
  • UBS Group first reported a position in BioCryst Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's BioCryst Pharmaceuticals position peaked at $50.3M in Q2 2025.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.